Literature DB >> 20164218

Human T-lymphotropic virus type 1 transcription and chromatin-remodeling complexes.

Rebecca Easley1, Lawrence Carpio, Irene Guendel, Zachary Klase, Soyun Choi, Kylene Kehn-Hall, John N Brady, Fatah Kashanchi.   

Abstract

Human T-lymphotropic virus type 1 (HTLV-1) encodes the viral protein Tax, which is believed to act as a viral transactivator through its interactions with a variety of transcription factors, including CREB and NF-kappaB. As is the case for all retroviruses, the provirus is inserted into the host DNA, where nucleosomes are deposited to ensure efficient packaging. Nucleosomes act as roadblocks in transcription, making it difficult for RNA polymerase II (Pol II) to proceed toward the 3' end of the genome. Because of this, a variety of chromatin remodelers can act to modify nucleosomes, allowing for efficient transcription. While a number of covalent modifications are known to occur on histone tails in HTLV-1 infection (i.e., histone acetyltransferases [HATs], histone deacetylases [HDACs], and histone methyltransferases [HMTs]), evidence points to the use of chromatin remodelers that use energy from ATP hydrolysis to remodel nucleosomes. Here we confirm that BRG1, which is the core subunit of eight chromatin-remodeling complexes, is essential not only for Tax transactivation but also for viral replication. This is especially evident when wild-type infectious clones of HTLV-1 are used. BRG1 associates with Tax at the HTLV-1 long terminal repeat (LTR), and coexpression of BRG1 and Tax results in increased rates of transcription. The interaction of BRG1 with Tax additionally recruits the basal transcriptional machinery and removes some of the core histones from the nucleosome at the start site (Nuc 1). When using the BRG1-deficient cell lines SW13, C33A, and TSUPR1, we observed little viral transcription and no viral replication. Importantly, while these three cell lines do not express detectable levels of BRG1, much of the SWI/SNF complex remains assembled in the cells. Knockdown of BRG1 and associated SWI/SNF subunits suggests that the BRG1-utilizing SWI/SNF complex PBAF is responsible for HTLV-1 nucleosome remodeling. Finally, HTLV-1 infection of cell lines with a knockdown in BRG1 or the PBAF complex results in a significant reduction in viral production. Overall, we concluded that BRG1 is required for Tax transactivation and HTLV-1 viral production and that the PBAF complex appears to be responsible for nucleosome remodeling.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20164218      PMCID: PMC2863730          DOI: 10.1128/JVI.00851-09

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  76 in total

1.  Anchoring of CREB binding protein to the human T-cell leukemia virus type 1 promoter: a molecular mechanism of Tax transactivation.

Authors:  H A Giebler; J E Loring; K van Orden; M A Colgin; J E Garrus; K W Escudero; A Brauweiler; J K Nyborg
Journal:  Mol Cell Biol       Date:  1997-09       Impact factor: 4.272

2.  Human T-cell leukemia virus type 1 Tax and cell cycle progression: role of cyclin D-cdk and p110Rb.

Authors:  C Neuveut; K G Low; F Maldarelli; I Schmitt; F Majone; R Grassmann; K T Jeang
Journal:  Mol Cell Biol       Date:  1998-06       Impact factor: 4.272

3.  Human T-cell leukemia virus type 1 Tax releases cell cycle arrest induced by p16INK4a.

Authors:  K G Low; L F Dorner; D B Fernando; J Grossman; K T Jeang; M J Comb
Journal:  J Virol       Date:  1997-03       Impact factor: 5.103

4.  The CBP co-activator is a histone acetyltransferase.

Authors:  A J Bannister; T Kouzarides
Journal:  Nature       Date:  1996 Dec 19-26       Impact factor: 49.962

5.  Catalytic activity of the yeast SWI/SNF complex on reconstituted nucleosome arrays.

Authors:  C Logie; C L Peterson
Journal:  EMBO J       Date:  1997-11-17       Impact factor: 11.598

6.  Human T-cell leukemia virus type 1 Tax requires direct access to DNA for recruitment of CREB binding protein to the viral promoter.

Authors:  B A Lenzmeier; H A Giebler; J K Nyborg
Journal:  Mol Cell Biol       Date:  1998-02       Impact factor: 4.272

7.  An exposed KID-like domain in human T-cell lymphotropic virus type 1 Tax is responsible for the recruitment of coactivators CBP/p300.

Authors:  R Harrod; Y Tang; C Nicot; H S Lu; A Vassilev; Y Nakatani; C Z Giam
Journal:  Mol Cell Biol       Date:  1998-09       Impact factor: 4.272

8.  The coactivator CBP stimulates human T-cell lymphotrophic virus type I Tax transactivation in vitro.

Authors:  F Kashanchi; J F Duvall; R P Kwok; J R Lundblad; R H Goodman; J N Brady
Journal:  J Biol Chem       Date:  1998-12-18       Impact factor: 5.157

9.  The human T-cell leukemia virus type 1 oncoprotein Tax inhibits the transcriptional activity of c-Myb through competition for the CREB binding protein.

Authors:  M A Colgin; J K Nyborg
Journal:  J Virol       Date:  1998-11       Impact factor: 5.103

10.  HTLV-I Tax protein binds to MEKK1 to stimulate IkappaB kinase activity and NF-kappaB activation.

Authors:  M J Yin; L B Christerson; Y Yamamoto; Y T Kwak; S Xu; F Mercurio; M Barbosa; M H Cobb; R B Gaynor
Journal:  Cell       Date:  1998-05-29       Impact factor: 41.582

View more
  21 in total

1.  Human T-lymphotropic virus type 1 Tax protein complexes with P-TEFb and competes for Brd4 and 7SK snRNP/HEXIM1 binding.

Authors:  Won-Kyung Cho; Moon Kyoo Jang; Keven Huang; Cynthia A Pise-Masison; John N Brady
Journal:  J Virol       Date:  2010-10-06       Impact factor: 5.103

Review 2.  Human T-lymphotropic virus proteins and post-translational modification pathways.

Authors:  Carlo Bidoia
Journal:  World J Virol       Date:  2012-08-12

3.  Novel Interactions between the Human T-Cell Leukemia Virus Type 1 Antisense Protein HBZ and the SWI/SNF Chromatin Remodeling Family: Implications for Viral Life Cycle.

Authors:  Ahlam Alasiri; Jorge Abboud Guerr; William W Hall; Noreen Sheehy
Journal:  J Virol       Date:  2019-07-30       Impact factor: 5.103

4.  Varying modulation of HIV-1 LTR activity by Baf complexes.

Authors:  Rachel Van Duyne; Irene Guendel; Aarthi Narayanan; Edward Gregg; Nazly Shafagati; Mudit Tyagi; Rebecca Easley; Zachary Klase; Sergei Nekhai; Kylene Kehn-Hall; Fatah Kashanchi
Journal:  J Mol Biol       Date:  2011-06-15       Impact factor: 5.469

5.  microRNA machinery is an integral component of drug-induced transcription inhibition in HIV-1 infection.

Authors:  Lawrence Carpio; Zachary Klase; William Coley; Irene Guendel; Sarah Choi; Rachel Van Duyne; Aarthi Narayanan; Kylene Kehn-Hall; Laurent Meijer; Fatah Kashanchi
Journal:  J RNAi Gene Silencing       Date:  2010-05-29

6.  Human T cell leukemia virus type 2 tax-mediated NF-κB activation involves a mechanism independent of Tax conjugation to ubiquitin and SUMO.

Authors:  Chloé Journo; Amandine Bonnet; Arnaud Favre-Bonvin; Jocelyn Turpin; Jennifer Vinera; Emilie Côté; Sébastien Alain Chevalier; Youmna Kfoury; Ali Bazarbachi; Claudine Pique; Renaud Mahieux
Journal:  J Virol       Date:  2012-11-07       Impact factor: 5.103

7.  Cotranscriptional Chromatin Remodeling by Small RNA Species: An HTLV-1 Perspective.

Authors:  Nishat Aliya; Saifur Rahman; Zafar K Khan; Pooja Jain
Journal:  Leuk Res Treatment       Date:  2012-02-09

8.  HTLV tax: a fascinating multifunctional co-regulator of viral and cellular pathways.

Authors:  Robert Currer; Rachel Van Duyne; Elizabeth Jaworski; Irene Guendel; Gavin Sampey; Ravi Das; Aarthi Narayanan; Fatah Kashanchi
Journal:  Front Microbiol       Date:  2012-11-30       Impact factor: 5.640

9.  Complex role of microRNAs in HTLV-1 infections.

Authors:  Gavin C Sampey; Rachel Van Duyne; Robert Currer; Ravi Das; Aarthi Narayanan; Fatah Kashanchi
Journal:  Front Genet       Date:  2012-12-17       Impact factor: 4.599

10.  Genome-wide determinants of proviral targeting, clonal abundance and expression in natural HTLV-1 infection.

Authors:  Anat Melamed; Daniel J Laydon; Nicolas A Gillet; Yuetsu Tanaka; Graham P Taylor; Charles R M Bangham
Journal:  PLoS Pathog       Date:  2013-03-21       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.